NIHR - Leeds Musculoskeletal Biomedical Research Unit (LMBRU)


Professor Paul Emery


ARUK Professor of Rheumatology



Mrs Gayle Iype (PA) 0113 392 4884


Division of Rheumatic and Musculoskeletal Disease
Chapel Allerton Hospital

Research Interests

Early arthritis

  • Early arthritis clinics
  • Prognosis/disease progression


  • Remission induction
  • Remission characterisation





Connective Tissue Diseases especially SLE/ScS/Vasculitis

Significant Publications

  • Edwards JCW, Szczepariski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.  Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis.  N Engl J Med, 2004;350:2572 81.
  • Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum, 2006; 54:1390-1400.
  • Dass D, Rawstron A, Vital E, Henshaw K, McGonagle D, Emery P.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum, 2008;58: 2293-9.
  • Xu SZ, Sukumar P, Zeng F, Li J, Jairaman A, English A, Naylor J, Ciurtin C, Majeed Y, Milligan CJ, Bahnasi YM, Al-Shawaf E, Porter KE, Jiang LH, Emery P, Sivaprasadarao A, Beech DJ. TRPC channel activation by extracellular thioredoxin. Nature, 2008;3;451:69-72.
  • Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfry CG, Hensor E, Wakefield RJ, O’Connor PJ, Emery P.  An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis.  Arthritis Rheum, 2008;58:2958-67.
  • Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig A, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early , moderate to severe, rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.  The Lancet, 2008;372:375-82.
  • Vital EM, Dass S, Rawstron AC, Buch MH, Goëb V, Henshaw K, Ponchel F, Emery PManagement of non-response to rituximab in rheumatoid arthritis: Predictors and outcome of retreatment. Arthritis Rheum, 2010;62:1273-9.
  • Emery P, van der Heijde D, Ostergaard M, Conaghan PG, Genovese MC, Keystone EC, Fleischmann R, Hsia EC, Xu W, Xu S, Rahman MU.  Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis, 2011;70:2126-30.
  • Villeneuve  E, Nam J. L , Bell M, Deighton C , Felson DT , Hazes JM ,  McInnes IB, Silman AJ , Solomon DH , Thompson A , White  PH, Bykerk V , Emery P. A Systematic Literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis,  Ann Rheum Dis 2012 [Epub ahead of print]
  • Saleem B, Brown AK, Quinn M, Karim Z, Hensor E, Conaghan PG, Peterfy CG, Wakefield R, Emery P. Can flare be predicted in DMARD treated RA patients in remission, and is it important? Ann Rheum Dis, 2012; Jan 31. [Epub ahead of print]


Paul Emery is the Arthritis Research UK Professor of Rheumatology and Head of the Academic Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom.   He is the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, U.K.

Professor Emery was President of EULAR 2009-2011, he is currently Past President.  He has served on the editorial boards of all the major rheumatology journals.  He was inaugural President of ISEMIR (International extremity MRI society).He is NIHR Senior Investigator. He is a recipient of the Roche Biennial Award for Clinical Rheumatology, the Rheumatology Hospital Doctor of the Year award 1999, EULAR prize 2002 for outstanding contribution to rheumatology research and the Carol Nachman Prize 2012

Professor Emery’s research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis, SpA and connective tissue diseases.  He has a special interest in the factors leading to persistent inflammation and is a founder member of ERAS, Leeds Early Arthritis Project (LEAP) and Yorkshire Early Arthritis Register (YEAR) and the Leeds Musculoskeletal Imaging Group.  He has published over 800 peer-reviewed articles in this area.


Sheffield – Gerry Wilson

York – Andy Rawstrom

Zurich – Stephen Gay/ Oliver Distler

Vienna – Josef Smolen

Grants Awarded



European Union



European Union


Senior Investigators Award



Leeds Musculoskeletal Biomedical Research Unit (LMBRU)



Programme Grant

Arthritis Research UK